Moreover, in Her2/neu+ breast cancer patients treated with trastuzumab plus vinorelbine, the expression level of CD47 was negatively correlated with the pathological response to treatment, and CD47 was significantly reduced in the complete responders (48). Here, ERBB2 is linked to breast carcinoma.